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Statement of Translational Relevance 
 
The degree of differentiation (usually termed “grade”) of colorectal cancers (CRC) is a well-
established tumour feature that is associated with patient prognosis, and its assessment forms 
part of the American Joint Committee on Cancer (AJCC) recommendations. 
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a highly conserved member of the AGC 
family of serine/threonine kinases. We have previously demonstrated that SGK1 expression 
in normal intestinal epithelium is highest at the top of the crypt, corresponding to the positions 
of differentiated colonocytes. In this study, we examine the role of SGK1 in intestinal cell 
differentiation, both in the normal crypt and in colorectal cancers. Our findings suggest that 
the level of SGK1 expression is a strong determinant of CRC differentiation status, identify c-
Myc inhibition and plakophilin 3 expression as important downstream mechanisms and 
demonstrate that increased expression of SGK1 in an orthotopic xenograft model reduces 
metastases. In human CRCs, lower SGK1 expression is associated with poorer differentiation 
and worse prognosis. Strategies to increase SGK1 pathway activity have potential use as anti-
metastatic agents, perhaps in the neo-adjuvant setting.  
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Abstract 
 
Background and Aims: The molecular events that determine intestinal cell differentiation are 
poorly understood and it is unclear whether it is primarily a passive event or an active process. 
It is clinically important to gain a greater understanding of the process, since in colorectal 
cancer (CRC), the degree of differentiation of a tumour is associated with patient survival. 
SGK1 has previously been identified as a gene that is principally expressed in differentiated 
intestinal cells. In colorectal cancer (CRC), there is marked downregulation of SGK1 
compared to normal tissue. Methods: An inducible SGK1 viral overexpression system was 
utilised to induce re-expression of SGK1 in CRC cell lines. Transcriptomic and phenotypic 
analyses of these CRC lines was performed and validation in mouse and human cohorts was 
performed. Results: We demonstrate that SGK1 is upregulated in response to, and an 
important controller of, intestinal cell differentiation. Re-expression of SGK1 in CRC cell lines 
results in features of differentiation, decreased migration rates, and inhibition of metastasis in 
an orthotopic xenograft model. These effects may be mediated in part by SGK1-induced PKP3 
expression and increased degradation of MYC. Conclusions: Our results suggest that SGK1 
is an important mediator of differentiation of colorectal cells and may inhibit CRC metastasis. 
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Introduction 
 
The unit structure of the normal large bowel is the crypt. Stem cells at the crypt base produce 
progeny that expand in number and differentiate as they pass to the lumen into which they are 
shed. Although the biology of the stem cell niche is relatively well understood, much less is 
known about the process of differentiation. The involvement of signalling pathways such as 
Wnt, TGFβ/BMP/Hedgehog, Notch and Ephrins is required for production of the main 
differentiated cell types (colonocyte, neuroendocrine, goblet, paneth). However, especially for 
colonocytes, it is unclear to what extent differentiation is a fundamentally passive process – 
for example, resulting from absence of microenvironmental Wnt activity, which declines as 
cells move up the crypt – or an active process, in which unknown pathways are switched on 
in order to drive the expression of genes involved in the functioning of the differentiated cells.  
 
The degree of differentiation (usually termed “grade”) of colorectal cancers (CRC) is a well-
established tumour feature that is associated with patient prognosis, and its assessment forms 
part of the American Joint Committee on Cancer (AJCC) recommendations [1]. The five year 
cumulative survival for patients with well-differentiated CRCs is 80.9%, compared with 76.9% 
and 45.5% for moderately and poorly differentiated lesions respectively [2]. Since CRC 
patients rarely die from effects of the primary cancer, poor differentiation must ultimately 
increase the risk of developing metastatic disease.  
 
The molecular pathways that determine CRC differentiation are incompletely described. There 
are two main theories to account for how an undifferentiated tumour might arise: (i) cancer 
cells are selected for their ability to down-regulate differentiation gene(s), the so-called “de-
differentiation” hypothesis; or (ii) differentiation reflects the cell of origin of the cancer in the 
crypt [3] [4]. However, whilst it is evident that CRCs demonstrate histological and growth 
characteristics similar to undifferentiated or stem cells in normal tissue, neither hypothesis 
fully explains why CRCs vary in their degree of differentiation.  
 
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a highly conserved member of the AGC 
family of serine/threonine kinases. It was originally identified as being transcriptionally 
activated in response to glucocorticoid stimuli in a mammary epithelial cell line [5]. SGK1 is 
also induced by various cell stresses and is involved in the cell survival response. Its 
transcription is influenced by different types of hormones, growth factors, cytokines and 
conditions of cellular stress [6]. SGK1 also regulates a number of other ion channels, including 
K+, Ca2+ and Cl- channels, and glucose transporters such as GLUT1 and SGLT1, thus 
controlling cell volume and osmolality [6]. In the colorectum, such proteins are expected to be 
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important in the functioning of differentiated colonocytes, since these cells primarily have a 
water-absorbing role. In keeping with this notion, we have previously demonstrated that SGK1 
expression in normal intestinal epithelium is highest at the top of the crypt, corresponding to 
the positions of differentiated colonocytes, with reduced expression in intestinal adenomas [7].  
 
Much remains unknown about SGK1’s function, and it appears to have a number of tissue-
specific effects in both normal cells and cancers. SGK1 has been proposed to form an 
alternative arm of Pi3 kinase (PI3K) signalling to the canonical AKT arm. AKT and SGK1 have 
very similar catalytic domains, recognising similar substrate motifs in vitro, and are both 
activated in a PI3K-dependent manner. This means that SGK1 potentially provides a parallel 
pathway to PI3K/AKT signalling and an alternative player in tumorigenesis [8][9]. SGK1 effects 
PI3K signalling through mTORC2 [10]. SGK1 is phosphorylated, and therefore activated, by 
PDKs. SGK1 expression is also regulated at the mRNA level, for example by Hippo pathway 
members Yap and Taz [11], and by glucocorticoid and mineralocorticoid receptors. 
Downstream, SGK1 phosphorylates the E3 ubiquitin ligase NEDD4-2, thus tagging it for 
degradation and allowing sodium channel expression. Other SGK1 targets include Foxo3, 
NRDG1 and MNK1. Nuclear SGK1 may also play a role in the epigenetic control of gene 
expression [12]. SGK1 activation has been proposed as a mechanism of cancer resistance to 
PI3K inhibitors [13]. There have been few studies of SGK1 in CRC. The kinase inhibitors SI113 
and EMD638683 have anti-SGK1 activity and have been demonstrated to inhibit the growth 
of RKO and CACO2 CRC cells respectively [14], often in combination with genotoxic therapies 
[15]. Sgk1 knockout has also been reported to reduce intestinal tumour numbers in mice with 
germline Apc mutations [16].  
  
In this study, we examine the role of SGK1 in intestinal cell differentiation, both in the normal 
crypt and in colorectal cancers. We determine the consequences of SGK1 re-expression for 
CRC behaviour in model systems in vitro and in vivo, and identify c-Myc inhibition and 
plakophilin 3 expression as important downstream mechanisms. Finally, we test for 
associations between SGK1 levels and the clinico-pathological features of a set of sporadic 
CRCs. Our findings suggest that the level of SGK1 expression is a strong determinant of CRC 
differentiation status, supporting the cancer “de-differentiation” hypothesis. We also 
demonstrate that the differentiation status of a cancer is strongly associated with its metastatic 
potential. Our findings potentially open new avenues for research into CRC metastasis. 
 
Materials and methods 
 
Cell lines and cell culture 
Research. 
on October 22, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1033 
6 
 
Human CRC cell lines were obtained from collaborators, and are commercially available from 
the American Type Culture Collection (ATCC): HT29 (ATCC® HTB-38™), LS174T (ATCC® 
CL-188™), SW480 (ATCC® CCL-228™). Murine MC-38 cell line is commercially available 
from Kerafast (ENH204). All CRC cell lines were grown in DMEM. Media were supplemented 
with 10% foetal calf serum and 1% penicillin/streptomycin, and incubated at 37°C and 5% 
CO2. For sodium butyrate treatment, cells at 80% confluence were treated with 5mM NaBut 
diluted in medium. Mycoplasma status was tested prior to each experiment using the Lonza 
Mycoalert mycoplasma detection kit (LT07-218). 
 
NaBut and expression of luciferase 
A 1.7kb region upstream of the start codon of rat Sgk1 was cloned into the pGL3-enhancer 
vector. Cells were transiently transfected with either of the Sgk1 promoter-pGL3 constructs 
and the Renilla luciferase pGL4.75 vector (Promega), as a control for transfection efficiency. 
Twenty-four hours after transfection, experimental cells were treated with 5mM NaBut and 
luciferase activity was measured 48 hours later with the Dual-GloTM Luciferase Assay System 
(Promega). 
 
Generation of SGK1-expressing construct 
For lentivirus production, a 3X-FLAG tag was added to the 3’ end of the full coding sequence 
of human SGK1. Transcription of SGK1 sequences was initiated by the CMV promoter, 
regulated by the Tet operon in a Tet-Off regulated manner.  
 
Western Blotting 
Cells were harvested in lysis buffer supplemented with protease and phosphatase inhibitors 
(Roche). Protein content was measured by BCA assay (Pierce) and equal amounts were run 
onto pre-cast 4-12% NuPage gels (Invitrogen). Blotted membranes were blocked in 5% 
skimmed milk in PBS and incubated with the indicated primary and secondary antibodies.  
 
Immunocytofluorescence 
Cells were grown in confocal dishes with cover glass bottom (PAA), fixed in 3.7% 
paraformaldehyde for 10 minutes at room temperature and permeabilised with 0.1% TritonX-
100 in PBS for 5 minutes at room temperature. Fixed cells were incubated either with serum 
obtained from the species in which the secondary was raised or with 1% BSA to prevent non-
specific binding. Cells were then incubated with primary antibodies for 1 hour, rinsed, 
incubated with fluorescently-labelled secondary antibodies for 1 hour in the dark, and finally 
washed and counterstained with DAPI (Sigma). Samples were analysed with the ZEISS 510 
MetaHead confocal microscope.  
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Tissue Microarrays 
TMAs (CO484a, CO485) were obtained from Insight Biotechnology Ltd, the UK suppliers of 
US Biomax. They comprised histological sections of colon cancer specimens with information 
on TNM and clinical stage, differentiation and pathological grade. Scoring for SGK1 protein 
expression was performed following IHC on a scale of 1-5 for each specimen.  
 
Microarrays and SGK1 expression from villi and crypts 
Endoscopic biopsies were taken from the descending colon of five normal control patients and 
were microdissected into crypt tops and bottoms. RNA was extracted, amplified and quantified 
using Illumina beadchip microarrays. Analysis was performed using the R package “limma”.  
 
RNA sequencing  
RNA was isolated from pelleted cells using the Qiagen Rneasy MinElute clean-up kit and 
analysed using Tapestation. RNA sequencing libraries were prepared using the QuantSeq 3’ 
mRNA library prep kits (Lexogen) and sequencing performed on an Illumina Hiseq 4000 with 
75bp paired end reads. RNA sequencing for the CRC cell lines were performed in duplicate 
and for animal experiments in triplicate. Sequencing was performed to an average depth of 5 
million reads. Reads were de-multiplexed and mapped using Hisat2 to the reference human 
genome GRCh37. Feature counting was performed using Htseq version 0.6.1 and read 
normalisation and differential expression, using DESeq version 1.10.1. JavaGSEA was used 
using the Molecular Signatures Database on pre-ranked lists to perform gene set enrichment 
analysis. Curated signatures for cellular senescence, apoptosis and proliferation were 
obtained from published genesets [17].  
 
Proliferation and apoptosis  
Cell proliferation was measured with the CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay (Promega). Apoptosis was measured with the Caspase-Glo 3/7 Assay (Promega) 
under basal conditions and upon osmotic stress stimulus, achieved by treating the cells with 
500mM sorbitol (Sigma) for 24 hours.  
 
Anchorage-independent growth assay 
Anchorage-independent growth was measured as the ability of cells to form colonies in soft 
agar. Briefly, a bottom layer consisting of 0.6% agar (Sigma, A9414) diluted in tissue culture 
medium was plated out in 6-well plates. Equal numbers of cells were diluted in 0.3% agar in 
tissue culture medium and plated onto the bottom layer at a concentration of 1000 cells per 
well, in triplicates. Cells were incubated for three weeks and fed with 200μl of medium twice 
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weekly. Images were acquired with a scanner and the number of colonies formed was counted 
for each well.  
 
Boyden transwell assay 
8uM transwell assays were obtained from Corning and 300,000 cells were trypsinised and 
suspended in DMEM with 0% FBS and placed in the upper chamber. DMEM with 10% FBS 
was placed in the lower chamber. 16 hours later, cells were removed from the upper chamber 
and cells on the lower surface of the transwell assay were stained using Kwik-Diff stains 
(ThermoScientific). Automated cell counting was performed using the Nikon NIS Elements 
software package.  
 
Stable isotope labelling of amino acids in culture (SILAC) 
SILAC was performed with the SILAC Protein Quantitation Kit (ThermoScientific/Pierce) 
according to instructions. HT29-SGK1 cells were cultured in ‘heavy’ medium (13C6Lys + 
13C6/15N4Arg) and HT29 parental cells in ‘light’ medium in the presence of doxycyline for 5 
passages, after which incorporation of the heavy label was measured by tandem mass 
spectrometry. Resulting peptides were analysed by LC-MS/MS using an Ultimate3000™ 
HPLC system coupled on-line to a 3D high-capacity ion trap tandem mass spectrometer via a 
pneumatically assisted nano-electrospray source as described previously [18].  
 
Mouse models 
Animals were a mix of 5-10 week old male and female JAX™ NSG mice (NOD.Cg-Prkdcscid 
Il2rgtm1WjI/SzJ) obtained from Charles River Laboratories, UK. Animals were maintained 
under specific pathogen-free conditions, and food and water were supplied ad libitum. Housing 
and all procedures involving animals were performed according to protocols approved by the 
United Kingdom Home Office, in compliance with Animals (Scientific Procedures) Act and 
home office guidelines on animal welfare. Orthotopic implantation of tumours was performed 
on 5-10 week old mice under anaesthesia by isofluorane inhalation, using a 30 gauge custom-
made needle under direct endoscopy vision with the Coloview system (Karl Storz) [19].  
 
TCGA human cohort data 
The human cohort data was obtained from The Cancer Genome Atlas (TCGA) which is 
publically available for the scientific research community. Ethical approval for the data was 
obtained from the National Institute of Health (NIH). 
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Results 
 
SGK1 is preferentially expressed in intestinal tissue compartments comprised of differentiated 
cells 
 
In order to confirm that expression of SGK1 alters along the crypt axis of the colon and small 
intestine, endoscopic biopsies from the terminal ileum and colon from 5 patients were obtained 
and microdissected into crypt tops and bottoms. RNA was extracted and global gene 
expression was quantified using microarrays. SGK1 expression was 9.6-fold higher in small 
bowel villi than crypts (p=0.003) and 10.8-fold higher in colonic crypt tops than bottoms 
(p=0.1), consistent with previous data showing that SGK1 is expressed predominantly in 
differentiated enterocytes and colonocytes. Increased expression of SGK1 was associated 
with increasing expression of SHBG, CIDEC, DUSP5 and MAF, known drivers of 
differentiation in cell lines. DUSP5 was especially interesting, as low expression is known to 
be associated with poor tumour differentiation, lymph node metastasis, distant metastasis and 
poorer overall survival [20]. Expression of SGK1 was negatively associated with expression 
of ASCL2, OLFM4, EPHB2, RETNLB, MSI1 and SOX9, genes associated with stem cell 
maintenance and function (Supp. Table 1). 
 
Since CRCs are typified by reduced differentiation, we compared the levels of SGK1 mRNA 
in CRCs with those in normal intestine (data from The Cancer Genome Atlas). SGK1 
expression was >10-fold lower in the former (Supp. Figure 1). In keeping with this, SGK1 was 
recently identified as a “hub gene”, the reduced expression of which is central to a set of gene 
expression changes in colorectal carcinogenesis (24). 
 
 
Agents that cause differentiation of colorectal cells also induce SGK1 mRNA expression 
 
Sodium butyrate (NaBut) is a short-chain fatty acid normally found in the colorectal lumen. 
NaBut promotes cellular differentiation in vitro in a number of CRC cell lines (26). Since our 
data showed SGK1 to be upregulated in differentiated cells of the intestine, at the crypt tops, 
we investigated whether SGK1 expression was induced by NaBut-driven differentiation in 
CRC lines. Two cell lines were selected, LS174T which expresses almost no endogenous 
SGK1, and HT29 which expresses modest levels [23]. Upon NaBut treatment, both HT29 and 
LS174T cells showed a significant increase in SGK1 transcript levels over time, as measured 
by qRT-PCR (p<0.01) (Figure 1A). This increase was confirmed in luciferase reporter assays 
(3.9-fold for HT29, 1.7-fold for LS174T; data not shown). 
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SGK1 expression induces differentiation of CRC cells 
 
The NaBut experiments demonstrated that SGK1 is induced by differentiating agents. Based 
on these data and the SGK1 expression pattern in the crypt, we pursued the hypothesis that 
SGK1 is a key player in signalling pathways that induce and directly control differentiation of 
colorectal cells. To determine experimentally if this could be the case, we developed a system 
to establish stable, inducible expression of SGK1 using a lentivirus-based system. HT29 and 
LS174T CRC cell lines were used as models and comparisons made to their control 
counterparts that had been transduced with an empty lentivirus (HT29-SGK1 vs. HT29-WT, 
LS174T-SGK1 vs. LS174T-WT). This system resulted in levels of SGK1 mRNA expression 
that were comparable to those in normal intestinal tissues (Supp. Figure 2) and in the 
production of SGK1 protein (Supp. Figure 3). Taking this approach, it was possible to 
demonstrate that functionally active SGK1 protein was expressed, based on reduced levels 
of the known SGK1 phosphorylation target, NEDD4-2 (Supp. Figure 4). 
 
The process of differentiation in colonocytes is characterised by several histological features, 
including the formation of junctional complexes that maintain cell shape and the establishment 
of basal-apical cell polarity, with the formation of actin filament caps that co-localize with apical 
markers in differentiated colonocytes [24]. Upon NaBut-induced differentiation, LS174T cells 
are known to undergo specific morphological changes, which include the appearance of 
mucin-like granules [21]. We found that similar morphological changes were induced by re-
expression of SGK1 in the absence of NaBut, and there was an increased tendency for cells 
to grow as colonies. HT29 cells treated with NaBut or in which expression of SGK1 was 
induced, showed comparable morphological changes (Supp. Figure 5).  
 
We investigated whether other features of differentiation could be identified in our CRC cell 
lines following re-expression of SGK1, specifically investigating the levels and distribution of 
proteins important for the formation of key junctional proteins, beta-catenin, ZO-1 and E-
cadherin. SGK1 caused an increase in total ZO-1 but not beta-catenin (Figure 1B, Supp. 
Figure 6). Immunofluoresence analysis of E-cadherin demonstrated increased membrane 
expression following SGK1 re-expression, and this was confirmed following cell fractionation 
western blotting (Figure 1C). We then assessed markers of cell polarity, which is a feature of 
differentiated intestinal epithelial cells. We found that LS174T and HT29 displayed actin caps 
upon re-expression of SGK1, and these were not seen in control cells. Moreover, the apical 
marker villin, which showed diffuse cytoplasmic expression in control cells, co-localised with 
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the actin caps (Figure 1D). Together these findings demonstrated the ability of SGK1 re-
expression to induce colonocyte differentiation.  
 
We also transiently expressed SGK1 in the HCT116 CRC cell line, which has very low 
endogenous SGK1 and does not spontaneously differentiate in culture, perhaps having 
irreversibly lost the ability to do so. Following transient high-level SGK1 expression, HCT116 
cells ruptured, with no evidence of differentiation.  
 
 
SGK1 re-expressing CRC lines demonstrate reduced tumorigenicity, characterised by 
decreased anchorage-independent growth and cellular migration. 
 
To understand the phenotypic changes in cells that are induced by SGK1, we performed a 
number of functional assays using the re-expression cell lines, HT29-SGK1 and LS174T-
SGK1. Twenty-four hours after re-expression of SGK1, we observed a significant reduction of 
~40% in apoptosis rates under basal conditions, and a more modest but significant reduction 
upon induction of osmotic stress with sorbitol (Figure 2A). Apoptosis rates subsequently 
increased over the time course of the experiment to reach levels comparable to or exceeding 
those of control cells (data not shown), suggesting that the SGK1-induced protection was only 
temporary, or that resistant clones had grown out. SGK1 re-expression also led to modest, 
but significant, reductions in proliferation in the SGK1 re-expressing cells compared to controls 
(Figure 2A), and this was maintained over time.  
 
To probe the effects of SGK1 on stem-like cell properties, colonosphere formation assays 
were performed. Upon re-expression of SGK1, both HT29 and LS174T cell lines showed 
dramatically impaired formation of colonospheres (Figure 2B), in keeping with SGK1-mediated 
reversion of the CRC cell lines to a more differentiated phenotype. To investigate the effects 
on anchorage-independent growth, soft agar assays were performed to assess characteristics 
observed in differentiated cells, anoikis (cell death) and the inability to proliferate, when there 
is loss of adhesion from the extracellular matrix. SGK1 re-expression results in reduced colony 
formation (Figure 2C).  
 
Finally, we performed a Boyden migration assay that assesses cellular motility across a 
transwell membrane towards a growth factor gradient. At 24 hours, re-expression of SGK1 
resulted in a significant reduction in rates of migration compared with cells that had been 
transduced with an empty lentiviral construct (Figure 2D). This observation was confirmed 
using a different approach, where a migration assay was performed on 11 CRC cell lines that 
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naturally expressed different amounts of SGK1. This assay identified that lines with low SGK1 
mRNA expression, such as LS174T and SW480, exhibited the highest migration rate whereas 
cell line with higher SGK1 (COLO205, SNU-C4, SW1222) demonstrated low cellular migration 
(Figure 2E).  
 
The Cancer Cell Line Encyclopaedia (CCLE) was then utilised to obtain SGK1 expression for 
a total of 43 metastatic and primary colorectal cancer cell lines. Of the 42 cell lines, 9 were 
derived from metastatic sites. Primary CRC lines expressed significantly higher SGK1 than 
lines derived from metastases (2.7 Transcripts Per Kilobase Million (TPM) vs 6.7 TPM, 
p<0.05), but expression was both low and variable (Supp. Table 2).  
 
In summary, these findings point towards a link between increased SGK1 expression and 
reduced proliferation, apoptosis, stem cell phenotype and motility.  
 
 
SGK1 re-expression results in enrichment of gene networks involved in cell differentiation and 
reduction of MYC signalling.  
 
SGK1 could in principle influence numerous gene networks through protein phosphorylation, 
thus amplifying environmental or other triggers for differentiation. To gain clues about the gene 
expression changes induced by SGK1, it was re-expressed in 7 CRC cell lines (GP2D, HT29, 
HCT116, LS174T, SW1222, SW480 and T84). Whole-transcriptome profiling was performed 
using 3’-RNA sequencing.  
 
Three genes were found to be differentially expressed: SGK1, NEFM, and RNA18S5 (p.adj 
all <0.05). To determine if there were more subtle changes in expression of genesets, GSEA 
using signatures from the MsigDB databases and curated genesets were performed. Re-
expression of SGK1 was associated with enrichment for gene networks involved not only in 
the “protein kinase cascade” and “stress-activated protein kinase signalling” as expected from 
existing data, but also for “cell polarity”, “differentiation” and “cell matrix adhesion”. A focussed 
analysis of cancer signalling pathways demonstrated that expression levels of genes in 
several pro-oncogenic pathways were significantly decreased following SGK1 re-expression. 
This effect was most pronounced for the gene sets “MYC targets” and “retinoblastoma/E2F 
signalling” (NES=-26.1 and -1.56 respectively, p<0.001 for both) (Figure 3A, Table 1). 
Following re-expression of SGK1, expression of MYC mRNA was reduced by 23.6% (p=0.03) 
and expression of c-Myc target PGK1 was reduced by 23.1% (p=0.03). 
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In CRC, c-Myc lies at the crossroads of many growth-promoting signal transduction pathways 
and plays a key role as a pro-metastatic transcription factor, regulating epithelial- to-
mesenchymal transition, cell-cell matrix interactions and cellular invasion in cell and murine 
models. In order to confirm reduction in c-Myc protein, we transduced CRC lines HT29 and 
SW480 with SGK1 re-expression lentivirus, a kinase dead SGK1 re-expression lentivirus or 
an empty lentiviral vector. Upon re-expression of SGK1, there was a consistent and significant 
decrease in c-Myc protein expression only in the cell lines carrying the SGK1 re-expression 
vector (mean reduction=56% at day 4 (Figure 3B, Supp. Figure 7). Using antibodies specific 
to phospho-Ser62 and phospho-Thr58, we demonstrated that there was a corresponding 
decrease in phosphorylation at both c-Myc Ser62 and Thr58 in the SGK1 re-expressing cells 
(Figure 3C).  
 
 
 
SGK1-induced differentiation is mediated by plakophilin 3  
 
We searched for proteins that were differentially expressed as a consequence of SGK1 re-
expression and hence were potential downstream effectors of SGK1-induced differentiation. 
We utilized stable isotope labelling of amino acids in culture (SILAC) on our HT29-SGK1 and 
parental cells, followed by mass spectrometry differential analysis. The experiment identified 
a small number of proteins showing differential expression upon SGK1 re-expression. Mass 
spectrometry results consistently indicated an increased abundance (~20-fold) of plakophilin 
3 (PKP3) (Figure 4A), an essential component of desmosomes that has been linked to 
metastatic potential and differentiation in tumours [25] [26]. Western blotting (Supp. Figure 8A) 
confirmed higher levels of PKP3 expression in both HT29-SGK1 and LS174T-SGK1 cells 
compared to parental cells. Investigation of PKP3 expression by immunohistochemistry in 
normal human colon showed increased expression in differentiated cells, paralleling SGK1 
expression (Figure 4B).  
 
To assess whether PKP3 mediates the effects of SGK1 on cell differentiation, we engineered 
lentiviral-based shRNA knockdown of PKP3 in HT29-SGK1 and LS174T-SGK1 cells. When 
compared to control cells re-expressing SGK1 and transduced with a non-targeting shRNA 
virus, abolition of PKP3 expression (Supp. Figure 8B) lowered membranous E-cadherin 
expression, and also restored colony-forming ability (Figure 4 C, D). 
 
 
Research. 
on October 22, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1033 
14 
 
SGK1 suppresses cancer cell metastasis in an orthotopic xenograft model through inhibition 
of metastatic outgrowth 
 
Our experiments demonstrated that SGK1 exerted diverse effects on the cancer cell 
phenotype. Many of the processes affected – differentiation, migration, anchorage-
independent growth, inter-cellular adhesion and c-Myc expression – are important in 
metastasis. We therefore developed an orthotopic xenograft mouse model of CRC metastasis, 
by endosocopically injecting genetically-modified CRC cells into the sub-mucosa of the mouse 
descending colon. We initially tested Sgk1 knockout in MC38 CRC cells, using a 
CRISPR/Cas9 strategy as part of a whole genome screen in 8 mice. Sgk1 knockout did not 
detectably change metastasis rates, as might be expected given the very low Sgk1 levels in 
CRCs (details not shown). We therefore tested the effects on metastasis of over-expressing 
SGK1. LS174T-SGK1 and LS174T-WT cells were labelled using a luciferase-expressing 
lentivirus (pHIV-Zsgreen-luc2) to enable in vivo imaging, and transplanted into Nod/Scid 
Gamma mice under endoscopic guidance. We found SGK1 mRNA expression in the LS174T-
SGK1 cell lines and primary xenografts to be at levels comparable to normal epithelium (data 
not shown).  
 
All animals (n=16) developed tumours in the colonic lumen following successful implantation. 
By day 21, mice became symptomatic principally due to intestinal obstruction but also 
metastatic outgrowth. All mice developed lung metastases, but secondary spread to the liver 
was uncommon (4/16 mice) and lesions in bone and other distant sites were not detected. At 
day 21, mice were culled, lungs were resected and ex vivo analysis performed.  
 
Ex vivo imaging demonstrated that there was a striking 25.8-fold decrease in lung metastasis 
burden (p<0.008) in the mice that received LS174T-SGK1 compared to those that received 
LS174T parental cells. In a replication cohort (n=15), there was a similar (20.4-fold) decrease 
in lung metastasis burden (p<0.001; Figure 5A, B). By contrast, there was no significant 
difference in primary tumour size between the LS174T-SGK1 and LS174T-WT groups (Supp. 
Figure 9A).  
 
These findings are in keeping with SGK1-mediated differentiation in vitro not limiting primary 
tumour growth, broadly consistent with the modest decreases in proliferation found in vitro 
(see above), but acting potently as a suppressor of metastasis. 
 
To determine the stage at which SGK1 exerted its effect on metastasis, whether inhibiting the 
ability of cells to migrate away from the primary tumour, or inhibiting later stages in metastasis 
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such as the ability of cells to survive in the circulation and enter metastatic tissues, a tail vein 
assay was performed. LS174T-SGK1 and LS174T-WT cells were injected into the tail veins 
of 8 Nod/Scid Gamma mice. Bioluminescence ex vivo analysis confirmed a marked reduction 
in metastasis in the LS174T-SGK1 cells, comparable in magnitude to the reduction seen in 
the orthotopic xenografts (p<0.001; Supp. Figure 9B).  
 
 
SGK1 expression levels are reduced in poorly differentiated human CRCs, but not in lymphatic 
metastases. 
 
Having established that SGK1 expression could induce features of differentiation in CRC cell 
lines, we examined this association in human CRCs. A tissue microarray of sporadic CRC 
resection specimens (n=86) was obtained comprising of cancers of principally stage II/III CRC 
and from patients with a mean age of 51.7 years (Supp. Table 3). Differentiation grading had 
been performed by accredited histopathologists according to AJCC guidelines. We examined 
SGK1 expression using immunohistochemistry (Supp. Figure 10). This demonstrated that 
there was a decrease in SGK1 expression in poorly differentiated than well or moderately 
differentiated cancers (t-test, p<0.01; Figure 5C). This result validated our experimental 
findings suggesting an association between low SGK1 expression and poor colorectal cancer 
differentiation in both CRC lines and tumour resections specimens. 
 
Low primary SGK1 expression is a biomarker of poor prognosis in different stages of human 
CRC 
 
Poor differentiation (high grade) is a well-known poor prognostic feature of CRC. 
Undifferentiated CRC are associated with increased cellular motility and features such as 
tumour and epithelial-mesenchymal transition (EMT) [27]. Patients with poorly differentiated 
CRCs tend to be younger, have larger, right-sided tumours with lymphovascular invasion, a 
higher frequency of MSI, a significantly poorer 4 year overall survival [28] and a higher 
propensity to develop metastasis [29]. As we have demonstrated the expression of SGK1 to 
be closely associated with CRC differentiation/grade, we sought to determine whether SGK1 
expression could be utilised as a similar marker of poor prognosis.  
 
The Cancer Genome Atlas sample set comprised an annotated set of US-based patient 
genomes with CRC of various stages [30]. A set of cohort of 284 patients has detailed follow-
up information and RNAseq had been performed on all specimens, enabling an analysis of 
the effect of SGK1 expression. SGK1 expression was expressed as quintiles as it was non-
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normally distributed and quintiles used as a quantitative variable. This analysis found a 
significant association between lower SGK1 expression and poorer survival (p=0.023) (Figure 
5D). There was no correlation between SGK1 expression and tumour stage and the 
association of low expression of SGK1 with poorer prognosis was observed across all stages 
of CRC except the small number of patients with stage 1 disease (Supp. Figure 11).  
 
 
Discussion 
 
SGK1 is a serine/threonine kinase that shares homology with proteins of the AKT family. To 
date, the role of SGK1 has been most clearly elucidated in regulation of ion channels [31], 
neuronal function [32] and T helper cell differentiation [33]. More recently, there has been a 
growing realization that SGK1 lies at the junction of, and could mediate the effects of, several 
oncogenic signalling networks. The effects of SGK1 are variable, depending on the tissues or 
cell lines analysed and the model systems used. A number of studies have highlighted the 
pro-proliferative effects of SGK1: in hepatocyte regeneration, SGK1 mediated the 
phosphorylation of ERK2 and the activation of the Ras-MAPK kinase pathway [34]; and in 
breast cancer, activation of SGK1 sustained mTOR activation in the context of AKT inhibition 
through direct phosphorylation of TSC2 [35]. SGK1 is also thought to act in conjunction with 
PHLPP1 to enable Ras-mutant cancers survive anoikis during metastasis [36]. By contrast, in 
HEK293 cells, SGK1 inhibited the Ras-MAPK kinase pathway through phosphorylation of B-
Raf, which is likely to exert an anti-proliferative effect [37].  
 
In terms of regulation of SGK1 expression, in CRC, mutations in SGK1 may be observed in 
up to 2% of cases, although the mutations are usually missense and not isolated to the kinase 
domain [38]. Our previous work has identified that down-regulation in CRCs appears to be 
independent of promoter hypermethylation [39] and these observations suggest that control 
is likely to be transcriptionally regulated.  
 
Our focus in this work was on the potential role of SGK1 in actively promoting differentiation, 
based on our validated finding that in the colorectum, SGK1 is expressed predominantly in the 
terminally differentiated epithelial cell compartment, in which cells have little proliferative 
potential, but are required to survive and function in a potentially hostile osmolar environment. 
We initially showed that SGK1 is induced by the extrinsic differentiating agent NaBut, 
consistent with NaBut acting, at least in part, through SGK1. Based on this preliminary 
evidence, we directly pursued the hypothesis that SGK1 re-expression induces features of 
differentiation. For this, we used both cellular and molecular read-outs in CRC cell lines that 
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retain some differentiation capability. We found that SGK1 induces not only a gene expression 
profile of differentiation, but also several specific features of differentiation, including cell 
polarity, increased tight junction protein expression, and relocation of adherens junction 
proteins to the membrane. Stem cell-like features, proliferation, apoptosis, growth in soft agar 
and migration were correspondingly decreased. Our data showed that mechanisms of SGK1 
action plausibly include reduction of c-Myc signalling, and increased expression of the 
desmosome protein plakophilin 3. In a CRC cell line orthotopic xenograft model, we found 
SGK1 re-expression to reduce the growth of lung metastases. The results of this assay 
suggested that SGK1-mediated differentiation of CRC lines inhibits the later stages of 
metastasis, perhaps functioning by limiting the ability of cells to migrate into the lung 
parenchyma from the endothelial cells. 
 
Some caveats must be applied to our data. First, SGK1 expression can be hard to assess 
using western blots/IHC, at least in part because the protein has multiple isoforms and there 
are few antibodies with good specificities. We therefore relied on mRNA expression using a 
pan-isoform probe or total isoform expression by sequencing as a read-out for many of our 
assays. We did, however, perform western blot analysis of tagged SGK1, a limited analysis of 
native SGK1, and also showed that functional SGK1 protein was produced based on 
assessment of NEDD4-2 levels. In combination, these experiments strongly supported the 
existence of active SGK1 in our experiments. Second, given the low SGK1 levels in CRC cell 
lines (including those with differentiation capacity) and the potential redundancy between 
SGK1 and related SGKs, our experiments necessarily relied on SGK1 re-expression rather 
than knock-down. Whilst we appreciate that over-expression of kinases can lead to non-
physiological effects, SGK1 re-expression in our systems led to near-physiological levels of 
mRNA. Finally, we have utilised an endoscopic transplantation model to determine effect on 
metastasis. The limitation of this approach is that as the lumen of the descending colon is 
narrow and mice become symptomatic relatively early. By contrast, the alternative, a caecal 
transplantation model allows mice to survive for a relatively longer period and often leads to 
increased levels of liver metastasis. We utilised the endoscopic transplantation model as it 
does not involve the creation of a track made from the external surface of the bowel and 
believe that, anatomically, the caecum of the mouse is markedly different from human.  
 
One largely unanswered question in the field is the differences and similarities between the 
AKT and SGK1 arms of the PI3K pathway. We speculate that whilst both arms promote cell 
survival, which may explain some of the data showing that loss of SGK1 is deleterious to cells 
(see above), SGK1 does this in the context of its additional function of promoting 
differentiation, particularly in the intestine. In human CRCs, features of differentiation are not 
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necessarily lost, with well and moderately differentiated cancers retaining some ability to form 
glandular units. Tumour differentiation is an important histological feature that is associated 
with poor cancer prognosis. The mechanisms through which the differentiation status of a 
tumour occurs and affects its behaviour and patient prognosis have, however, been somewhat 
overlooked. Our findings are consistent with the reduced expression of SGK1 being one 
important means by which tumours may “de-differentiate”, and acquire other malignant 
phenotypes such as migration and invasion. We conclude that a renewed focus on therapeutic 
agents to differentiate tumours, rather than simply to target cell survival, is justified. 
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TABLES 
 
Table 1. Top dysregulated pathways in cell lines re-expressing SGK1 compared with parental 
controls. The normalised enrichment core (NES) shows that SGK1 re-expressing cell lines 
have significantly less expression of gene sets such as Rb/E2F signalling, MYC targets and 
EMT, with increased expression of gene sets including differentiation, cell polarity and 
adhesion.  
 
Gene Set NES p-value 
Protein kinase cascade 1.34 0.004 
Cell polarity 1.70 0.010 
Regulation of cell differentiation 1.54 0.014 
Cell substrate adhesion 1.45 0.031 
Stress activated protein kinase signalling pathway 1.39 0.040 
Cell matrix adhesion 1.43 0.044 
Regulation of cell adhesion 1.47 0.047 
Epithelial morphogenesis -1.38 0.005 
Epithelial-mesenchymal transition -1.69 0.013 
MYC targets -2.61 <0.001 
mTORC1 signalling -2.61 <0.001 
Rb/E2F signalling -1.56 <0.001 
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FIGURES 
 
Figure 1. SGK1 causes colorectal cancer cell differentiation.  
A. SGK1 transcription is increased upon sodium butyrate (NaBut) treatment in colorectal 
cancer cells. The column chart plots fold-change increases in SGK1 transcript levels, as 
measured by qRT-PCR, in HT29 and LS174T colorectal cancer cells upon treatment with 
NaBut, normalized to untreated control and relative to levels at time=0 hrs. Both cell lines 
showed a significant increase in SGK1 between 0 and 24 hours, and between 24 and 48 hours 
(t-test, p<0.01 in all cases, experiments in triplicate). SGK1 levels plateaued after 48 hours in 
HT29, whereas a further significant increase was found in LS174T. 
B. Representative western blots of junctional proteins in HT29-SGK1 and LS174T-SGK1 cells 
and untreated wild-type controls. There are essentially unchanged levels of beta-catenin and 
an increase in ZO-1 abundance upon SGK1 re-expression. A similar ZO-1 increase was also 
found for cell line HCT116 (not shown).  
C. Representative immunofluorescence images suggest re-localisation of E-cadherin from the 
cytoplasm in parenteral controls (solid arrows) to the membrane in SGK1 re-expressing HT29 
(dashed arrows). The cellular fractionation blot confirms increased expression of E-cadherin 
in the membrane. Note that LS174T cells carry bi-allelic mutations of the CDH1 gene, resulting 
in protein absence.  
D. Immunofluorescence analysis on HT29-SGK1 and LS174T-SGK1 and parental controls 
illustrates the formation of actin ‘caps’ (green, arrowed), co-localised with the apical marker 
villin (red), in SGK1-transduced cells only. This indicates the establishment of cell polarity 
owing to SGK1 re-expression. 
 
 
Figure 2. Effects of SGK1-induced differentiation on colon cancer cell proliferation and 
tumorigenicity.  
A. The column chart displays ratios of HT29-SGK1 and LS174T-SGK1 proliferation (measured 
by tetrazolium compound assay) and apoptosis (basal and upon osmotic stress stimulation) 
24 hours after removal of doxycycline, relative to controls with doxycycline maintained. 
Proliferation and apoptosis were significantly reduced in SGK1-expressing cells (all t-test p-
values <0.05, experiments done in triplicate). 
B. Representative images show colonospheres formed by untransduced, GFP-transduced 
(GFP) and SGK1-transduced (SGK1) cells for HT29 and LS174T colorectal cancer cell lines. 
Images were acquired following 10 days of cell culturing conditions that favour stem cell 
growth and colonosphere formation. The column charts represent absorbance measurements 
from an endpoint tetrazolium compound assay (day 10), showing decreased proliferation rates 
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of the stem cell populations upon re-expression of SGK1 (t-test p-values<0.01 in all cases; 
experiments done in triplicate). 
C. The column charts show numbers of colonies formed in soft agar by untreated, GFP-
transduced (GFP) or SGK1-transduced (SGK1) cells. Results are an average of three 
experiments (t-test p-values<0.005 in all cases). Below the chart are representative images 
displaying macroscopic differences between untreated controls or SGK1-transduced cells.  
D. Cellular migration is reduced on SGK1 re-expression (reduction in migration rate 43% for 
LS174T and 62% for HT29; t-test, p<0.01 and p<0.0001 respectively.  
E. SGK1 mRNA expressions and CRC baseline migration rate. There is a significant negative 
correlation (Pearson correlation=0.68, p=0.02) between native SGK1 expression levels and 
migration in a panel of CRC lines (COLO205, GP2D, HCT116, HT29, LS174T, LS180, SNU-
C4, SW1222, SW48, SW480, T84). Note that higher deltaCt corresponds to lower SGK1 
expression. 
 
 
Figure 3. Reduced expression of MYC and its targets after SGK1 re-expression.  
A. Gene set enrichment analysis of RNA sequencing data shows greatly reduced expression 
of c-Myc target genes following SGK1 re-expression.  
B. Representative western blots demonstrating reduced MYC protein expression following 
SGK1 re-expression in HT29 and SW480, but not after re-expression of a kinase-dead 
SGK1.  
C. Representative western blots demonstrating decreased total MYC and total phospho-
MYC (Ser62 and Thr58) following SGK1 re-expression in HT29, LS174T and SW480 cell 
lines.  
 
 
Figure 4. Plakophilin 3 is induced by SGK1 and in turn mediates features of differentiation.  
A. Quantitative SILAC mass spectrometry reveals elevated PKP3 in SGK1 re-expressing cells. 
MS/MS spectrum shows PKP3-derived peptide 727-752, [M+3H]+ 884.2 (calculated MW 
2649.5Da), where the fragment ions are indicated (green: immonium ions; blue: y-ions; red: 
b-ions). The light (SGK1 expressing cells) versus heavy (control cells) ratio as well as the 
significance (P) are indicated.  
B. Immunohistochemistry on paraffin sections derived from normal human colonic tissue 
shows that expression of PKP3 is stronger in the differentiated compartment of the colonic 
crypt (boxed), where SGK1 is also expressed, that in the proliferative compartment (arrowed).  
C. The bar chart represents the number of colonies formed in soft agar for HT29-SGK1 and 
LS174T-SGK1 cells with PKP3 knock-down (grey bars) or non-targeting shRNA (black bars), 
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showing that SGK1-induced impaired anchorage-independent growth is reversed upon PKP3 
knock-down (t-test p-values<0.005 in all cases). 
D. Immunofluorescence shows that the SGK1-induced re-localisation of E-cadherin to the cell 
membrane is impaired upon PKP3 knockdown by shRNA compared with non-targeting shRNA 
controls. Representative western blots demonstrating decreased total E-Cadherin when 
SGK1 re-expressing cells are subjected to PKP3 knockdown by shRNA compared with non-
targeting shRNA controls (results for LS174T cells not shown due to E-cadherin deficiency). 
 
 
Figure 5. SGK1 re-expression reduces lung metastases in an orthotopic xenograft model of 
CRC and is associated with poor differentiation and inferior prognosis in human CRCs.  
A. Ex vivo analysis of luminescence from lung metastases of LS174T-SGK1 and parental 
cells, demonstrates only very small lesions in the former. 
B. Lung metastasis burden after orthotopic delivery of LS174T-SGK1 is much lower than in 
parental cells. 
C. Immunohistochemical detection of SGK1 in a human CRC tissue microarray shows 
significantly less expression in poorly differentiated CRCs (p<0.01). 
D. Data from TCGA demonstrate that patients with the lowest expression of SGK1 have 
significantly poorer overall survival (p<0.001).  
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